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Abstract 
The beginnings of caring for critically ill patients date back to Florence Nightingale’s work during the Crimean War in 1854, but the 
subspecialty of critical care medicine is relatively young. The first US multidisciplinary intensive care unit (ICU) was established in 1958, 
and the American Board of Medical Subspecialties first recognized the subspecialty of critical care medicine in 1986. Critical care 
pharmacy services began around the 1970s, growing in the intervening 40 years to become one of the largest practice areas for clinical 
pharmacists, with its own section in the SCCM, the largest international professional organization in the field. During the next decade, 
pharmacy services expanded to various ICU settings (both adult and pediatric), the operating room, and the emergency department.  
In these settings, pharmacists established clinical practices consisting of therapeutic drug monitoring, nutrition support, and 
participation in patient care rounds. Pharmacists also developed efficient and safe drug delivery systems with the evolution of critical 
care pharmacy satellites and other innovative programs. In the 1980s, critical care pharmacists designed specialized training programs 
and increased participation in critical care organizations.    The number of critical care residencies and fellowships doubled between 
the early 1980s and the late 1990s.  Standards for critical care residency were developed, and directories of residencies and fellowships 
were published. In 1989, the Clinical Pharmacy and Pharmacology Section was formed within the Society of Critical Care Medicine, the 
largest international, multidisciplinary, multispecialty critical care organization. This recognition acknowledged that pharmacists are 
necessary and valuable members of the physician-led multidisciplinary team. The Society of Critical Care Medicine Guidelines for Critical 
Care Services and Personnel deem that pharmacists are essential for the delivery of quality care to critically ill patients.    These 
guidelines recommend that a pharmacist monitor drug regimen for dosing, adverse reactions, drug-drug interactions, and cost 
optimization for all hospitals providing critical care services. The guidelines also advocate that a specialized, decentralized pharmacist 
provide expertise in nutrition support, cardiorespiratory resuscitation, and clinical research in academic medical centers providing 
comprehensive critical care.  
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Introduction 
The value of critical care pharmacists has been well 
documented. Various studies have shown that critical care 
pharmacists reduce medication errors, improve patient 
outcomes, reduce costs and waste, and decrease mortality 
rates among patients with thromboembolic diseases or 
infections. It would therefore appear that critical care 
pharmacists should be a basic requirement for any ICU, because 
they are involved in diverse aspects of care and scholarly 
activities related to critically ill patients, because they  
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are well accepted by their peers, and because their work is 
associated with improved clinical, economic, and humanistic 
outcomes. The reasons why critical care pharmacists are not 
present all the time in any type of HCE are multifactorial and 
may include lack of financial resources, lack of adequately 
trained personnel, inconsistent documentation of pharmacists’ 
activities in medical records, lack of a shared practice model, 
and perhaps (however counterintuitive) the belief of both 
hospital and pharmacy administrators that critical care 
pharmacists are not really essential. However, critical care is a 
rapidly expanding pharmacy specialty, and today's pharmacy 
students have more opportunities than ever to become 
successful critical care pharmacists if they demonstrate their 
expertise and their commitment to the lives of their patients. 
Working as pharmacists in the intensive care unit begins with 
our ability to be engaged and meticulous in identifying key 
patient interventions. Pharmacists must be able to assess the 
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status of each organ and determine the patient’s problem list. 
Addressing the patient’s neurological status, checking vitals for 
hemodynamic stability, managing pain, and knowing when 
prophylaxis is indicated are all factors in providing a care plan 
for the patient. Along with the roles aforementioned, the 
pharmacist aids in evaluating the need for fluids, diuretics, or 
stool-inducing medications, while taking into consideration the 
patient’s input/output, nutritional status, and comorbidities. 
Additionally, pharmacists must remember to address liver 
function, as well as any drug monitoring parameters. Ensuring 
that patients are on their home medications, identifying 
possible intravenous to enteral agents, and verifying proper 
medications are also important in performing an intervention. 
Antibiotic stewardship is a core part of critical care, and many 
times, the physician will rely on the pharmacist’s 
recommendations and expertise. Critical care pharmacists are 
also recognized as essential by those outside the pharmacy 
profession, including the SCCM. In fact, several SCCM guidelines 
describe the scope of pharmacy practice and pharmacists’ role 
within best practice models for ICU staffing. A CJHP study 
highlights the potential role of critical care pharmacists in 
quality improvement, detection of errors, and production of 
scholarly work. Although less than 10% of hospitalized patients 
are admitted to the ICU, over 30% of hospital costs are allocated 
for patients needing acute care. It seems that patients admitted 
to ICUs are prone to a higher risk of medication-related 
problems because of the higher numbers of prescribed 
medications, intensity of the work environment, presence of 
critical illness, and increased use of high-risk medications. 
 
1.1. Scope of Pharmacists in critical care 
A survey of pharmacist services included only 382 of the 3,238 
hospitals (11.8%) with an ICU at the time of the survey. The 
exact number of pharmacists practicing in a critical care 
environment is not known. There are approximately 1,500 
pharmacist members of the SCCM Clinical Pharmacy and 
Pharmacology Section and about 3,000 critical care pharmacist 
members as part of the American College of Clinical Pharmacy 
and the American Society of Health System Pharmacists. This 
has led to a conservative estimate of 6,000 practicing critical 
care pharmacists. The time that these pharmacists dedicate to 
ICU services is unknown. It is projected that the demand for 
critical care pharmacists will remain stable or grow in the future 
[1]. 
 
1.2.  Role as a Team Member 
Clinical pharmacists in the ICU (and in other practice areas) are 
part of an interprofessional team working toward the common 
goal of improving patient outcomes. Teams in the ICU often 
include physicians, pharmacists, nurses, respiratory therapists, 
dieticians, physical therapists, social workers, and others. Each 
of these caregivers has a specific role in patient care, and each 
can contribute positively to patient outcomes. Because 
interprofessional critical care teams have been shown to 
benefit patients and their families, integrated team-based care 
is expressly included in the SCCM-envisioned future statement 
and guiding principles for the organization and members. The 
performance of teams is studied in many ways, including team 
processes. In the ICU, utilization of daily patient-centered goals 
checklists and commencement of daily multidisciplinary patient 
care rounds are associated with positive patient outcomes. 
Improving team interactions has been associated with positive 
patient outcomes, and poor team interactions have been 
associated with ICU adverse events. Pharmacists can play a role 
in ensuring that all patient goals are addressed by the team, 
clarifying tasks, developing care plans, and communicating 
plans among caregivers. In light of the positive impact of 
pharmacist participation on ICU interprofessional teams, each 
hospital should have a clinical pharmacist rounding and 
participating in other aspects of team-based patient care in the 
ICU [1-3]. 
 
2. Pharmacists’ role in critical care 
The use of medication by seriously ill patients represents an 
example of the complex nature of the care provided in the ICU. 
The reason for this complexity is that patients are usually 
subjected to poly-medication, which makes pharmacological 
treatment a significant risk factor for the occurrence of adverse 
events that might negatively interfere with the clinical 
progression of patients [4]. Pharmacists have been 
incorporated into ICU multi-professional staff to improve the 
care provided to patients, particularly by monitoring the drugs 
administered and assessing their efficacy, thus contributing to 
improving patient safety. The participation of clinical 
pharmacists in routine ICU care mainly includes active 
involvement in daily rounds, where they provide relevant 
information to the medical and nursing staff, analysis and 
monitoring of the efficacy of pharmacological treatments, 
implementation of medication reconciliation, and prevention, 
identification, and reporting of adverse reactions [5-7]. The 
actions performed by clinical pharmacists relative to the 
monitoring of pharmacological treatment are referred to as 
PhRs. Such professional interventions presuppose actions 
targeting pharmacological treatment to correct or prevent 
negative clinical outcomes derived from the use of medications. 
These are planned and documented actions performed with 
users and healthcare professionals, as they are a part of the 
process of monitoring/follow-up of pharmacological 
treatments [8]. 
 
2.1. Challenges encountered in the ICU 
Critical care areas present a particular challenge with regard to 
medication errors. They are a dynamic environment with 
critically ill patients who often require rapid adaptation of on-
going management. ICUs can be error-prone settings, where 
even otherwise minor adverse events can lead to serious 
disability. The frequency of medication errors in adult ICUs can 
be as high as 947 per 1,000 patient-days, with a median of 105.9 
per 1,000 patient-days. Medication errors are estimated to 
account for 78% of all medical errors in ICUs, with an average 
of 1.75 medication errors per patient per day. Not only are 
medication errors more frequent in ICU settings than in non-
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ICU settings, they are also more likely to be severe and cause 
harm [9]. 
 
2.2. Factors associated with morbidity in ICU 
Many factors are hypothesized to contribute to the relatively 
high incidence and associated morbidity of medication errors in 
the ICU. The patients themselves are the most complex and 
critically ill in the hospital setting. By virtue of being sicker, 
older, and having more comorbidities, these patients are less 
resilient to errors.  
 Because they require a higher intensity of care provision 
and may receive more medications, they may be at greater 
risk of iatrogenic harm. Pharmacokinetics of medications 
can also be altered in critically ill patients, principally 
through changes in volume of distribution and drug 
clearance. Large volume resuscitations, positive pressure 
ventilation, surgical procedures, systemic inflammatory 
response, and changes in protein binding, all common in 
ICU patients, affect the pharmacokinetics of many drugs.  
 In addition, these patients are usually unable to help 
facilitate their own care, a problem aggravated by the 
volume of transfers to and from ICUs. Medication safety in 
ICUs might also be compromised because of the risks 
associated with the use of multiple medications per patient 
and the use of high-risk drugs associated with potentially 
severe adverse events. Drugs used in the ICU are more 
likely to be potent, require dose calculations, have 
medication interactions, and be continuous infusions 
(which have a greater potential for error). Many 
medications may be used for off-label indications in the ICU 
setting, similar to the non-ICU inpatient and outpatient 
settings. The combination of these elements makes 
patients in critical care areas particularly vulnerable to 
medication errors and their potentially dire consequences.  
 Patients admitted to ICU with COPD often have multiple 
comorbidities and present with acute respiratory failure as 
a result of an infective exacerbation or at the end stage of 
their disease.  
 Atrial fibrillation (AF) is the most common arrhythmia 
encountered in the ICU. Preexisting AF is highly prevalent 
among older patients with chronic conditions who are at 
risk for critical illness, whereas new-onset AF can be 
triggered by accelerated atrial remodeling and 
arrhythmogenic triggers encountered during critical illness. 
The acute loss of atrial systole and onset of rapid 
ventricular rates that characterize new-onset AF often lead 
to decreased cardiac output and hemodynamic 
compromise. Thus, new-onset AF is both a marker of 
disease severity as well as a likely contributor to poor 
outcomes, similar to other manifestations of organ 
dysfunction during critical illness. Evaluating immediate 
hemodynamic effects of new-onset AF during critical illness 
is an important component of rapid clinical assessment 
aimed at identifying patients in need of urgent direct 
current cardioversion, treatment of reversible inciting 
factors, and identification of patients who may benefit 
from pharmacologic rate or rhythm control. In addition to 
acute hemodynamic effects, new-onset AF during critical 
illness is associated with both short- and long-term 
increases in the risk of stroke, heart failure, and death, with 
AF recurrence rates of approximately 50% within 1 year 
following hospital discharge. In general ICU patients, 
incidence of new-onset AF was more than 11% with a high 
impact on morbidity and mortality, particularly associated 
with the presence of ARF.  
 Variables that have been commonly linked to an increased 
risk for in-hospital mortality in mechanically ventilated 
patients include age, comorbidities, SAPS III, severe ARDS, 
deep sedation, duration of MV, and ICU complications. 
However, there is a wide variation in the prognostic 
variables between studies, which may be related to 
differences in the characteristics of patient cohorts, clinical 
variables recorded, and the geographical setting of 
different studies. 
 Patients in ICU are usually at high risk of mortality not only 
from their critical illness but also from secondary 
complication such as nosocomial infection. Nosocomial 
pneumonia, a common ICU infection, affects 27% of all 
critically ill patients, where 86% of it is associated with 
mechanical ventilation. The mortality rate for VAP 
(hospital-acquired/nosocomial pneumonia hat develops 
more than 48–72 h after endotracheal intubation) ranges 
between 27% to 76%. Pseudomonas or Acinetobacter 
pneumonia is associated with higher mortality rates than 
those associated with other organisms. 
 Delirium is a multifactorial entity, and its understanding 
continues to evolve. Delirium has been associated with 
increased morbidity, mortality, length of stay, and cost for 
hospitalized patients, especially for patients in the ICU. 
Recent literature on delirium focuses on specific 
pharmacologic risk factors and pharmacologic 
interventions to minimize course and severity of delirium. 
While medication management clearly plays a role in 
delirium management, there are a variety of 
nonpharmacologic interventions, pharmacologic 
minimization strategies, and protocols that have been 
recently described. 
 There has been an increase in the number of       patients 
undergoing open heart operation with the prolongation of 
life expectancy and medical advances. It has been reported 
that approximately 19%–45% of the cases may go through 
prolonged intensive care after open heart operation. In 
some studies, advanced age, female gender, reduced left 
ventricular function, arrhythmia, inotropic agent support 
and IABP requirements have been identified as risk factors 
for prolonged intensive care.  Cardiac arrest following 
neurosurgery (craniotomy and spine surgery) is a 
devastating complication associated with significant 
postoperative morbidity and mortality [9-18]. 
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Exhibit 1. Definition of Potential errors in ICU [22] 
Medical error The failure of a planned action to be completed as intended or the use of a wrong 
plan to achieve an aim. 
Medication error Any error in the medication process, whether there are adverse consequences or not. 
ADE Any injury related to the use of a drug. Not all adverse drug events are caused by 
medical error, nor do all medication errors result in an adverse drug event. 
Preventable adverse 
events 
Harm that could be avoided through reasonable planning or proper execution of an 
action. 
Near miss The occurrence of an error that did not result in harm. 
Slip A failure to execute an action due to a routine behavior being misdirected. 
Lapse A failure to execute an action due to lapse in memory and a routine behavior being 
omitted. 
Mistake A knowledge-based error due to an incorrect thought process or analysis. 
Error of omission Failure to perform an appropriate action. 
Error of commission Performing an inappropriate action. 
 
2.3.  Medication Errors in ICU 
Medication errors are the most common type of medical errors 
critical care patients experience.  In the ICUs, on average, 
patients exposed to 1.7 errors per day and medication errors 
account for nearly 80% of serious medical errors. Patients in the 
ICUs receive more drugs than patients in the other units. 
Critically ill patients are prescribed twice as many medications 
as patients outside of the ICU and nearly all will suffer a 
potentially life-threatening error at some point during their 
stay. They are vulnerable to ADEs because of changing organ 
function leading to alterations in the pharmacokinetics of 
drugs, complex drug regimens, and fast-paced decision-making. 
Also, the severity, length of stay, and costs associated with ADEs 
are greater in the ICU compared to general care units. Because 
of drowsiness or unconsciousness, ICU patients are not able to 
monitor and report the ADRs: thus, medication errors occur 
more often and have serious consequences. Intensities of 
medication errors are minor, severe, and life-threatening 
leading to death. Medication errors lead to an increase in the 
duration of hospitalization and disability and death in up to 
6.5% of hospital admissions. Critical care medication errors 
occur most frequently in the administration phase. 
Administration errors include errors associated with infusion 
rates, incorrect or omitted doses, administration time, and 
physiochemical incompatibility of parenterally administered 
products. Most medications in the ICU are administered as 
weight-based infusions. These infusions require mathematical 
calculations and frequently are based on estimated weights 
increasing the risk of error. Potassium chloride, heparin, 
magnesium sulphate, vasoactive drugs, sedatives, and 
analgesics as the medications with the greatest risk of error in 
ICU. Antibiotics frequently are empirically prescribed in the ICU 
and errors have potential implications both for individual 
patients and populations. Cardiovascular drugs, antibiotics, 
sedatives/analgesics, and electrolytes were the drug categories 
most associated with errors. Patients are prescribed these 
medications in an environment that is stressful, complex, 
changing, under the stewardship of multiple providers, and 
frequently managing patients in crisis. Moreover, they are 
reliant on sophisticated technologies and equipment to deliver 
essential care and yet relatively little is known about medical 
equipment failures and the associated safety risks. Critical care 
pharmacist group consensus on the most important medication 
error reduction resources was established. Pharmacists 
working on high-resourced units made more clinically 
significant medicines optimizations [9], [19-23]. 
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Exhibit 2. Risk factors for medication errors in the intensive care unit [22] 
Factors Specific risk factors 
Patient Severity of illness 
 Strongest predictor of ADE  
 ICU patients more likely to experience ADE than patients in other units  
Extreme of ages 
Increased susceptibility to ADEs  
Prolonged hospitalization 
Increased exposure and susceptibility to ADEs  
Sedation 
Patients unable to participate in care and defend themselves against errors  
Medications Types of medications 
 Frequent use of boluses and infusions  
 Weight-based infusions derived from estimated weights or unreliable 
determinations  
 Mathematical calculations required for medication dosages 
 Programming of infusion pumps 
Number of medications 
 Twice as many medications prescribed as for patients in other units  
 Increased probability of medication error and medication interactions  
Number of interventions 
Increased risk of complications  
ICU  
environment 
Complex environment 
 Difficult working conditions make errors more probable 
 High stress  
 High turnover of patients and providers  
Emergency admissions 
Risk of an adverse event increases by approximately 6% per day  
Multiple care providers 
Challenges the integration of different care plans  
 
2.4. Working with Patients and Their Families 
Having a loved one in an ICU can impair family integrity, 
making some changes in family roles and responsibilities. Four 
themes emerged as important to families: information, 
clinician skills, ICU environment, and discharge from the ICU. 
Relatives often lack important information about intensive 
care unit patients. High-quality information is crucial to help 
relatives overcome the often-considerable situational stress 
and to acquire the ability to participate in the decision-making 
process, most notably regarding the appropriate level of care. 
Fear of death or permanent disability, uncertainty about the 
patient's condition and prognosis, emotional conflicts, 
financial concerns, role changes, and unfamiliarity of the 
intensive care environment, especially during the first 72 h 
after ICU admission, can trigger feelings of shock, anger, guilt, 
denial, despair, and depression within the family. 50% of U.S. 
hospital deaths occur during or after a stay in an ICU, and 
nearly 70% of ICU deaths involve an active decision to limit 
treatment. Because most ICU patients are not able to make 
decisions for themselves, family members must make these 
difficult decisions on behalf of their loved ones. When doing 
so, they may worry that their loved one has suffered or that 
they have given up too soon, and they frequently harbor 
lingering feelings of doubt, regret, and guilt. During this 
vulnerable time family members rely on healthcare 
professionals to guide them through the decision-making 
process. Patients and their families are being encouraged to 
participate in the patient's care. Communication with patients 
and their families in the ICU will continue to increase as 
families are being engaged in activities such as ICU team 
rounds. Families participating in patient care rounds for 
pediatric patients frequently initiated discussions of 
medications. Also, family participation in delirium prevention 
to avoid pharmacologic treatment is undergoing current 
consideration. Enhancing patient and family communication 
will result in greater satisfaction with care and a mitigation of 
ADR frequency and severity [1], [24-27]. 
 
2.5.  ICU Pharmacy Service Description 
Critical care pharmacy activities are associated with 
perceptions of beneficial clinical and financial outcomes. 
Fundamental services are viewed more favorably than 
desirable or optimal services, possibly because they occurred 
more frequently or were required for safe patient care. 
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Substantial inefficiencies may occur if pharmacy services 
disappeared. Considerable support existed for funding and 
reimbursement of critical care pharmacy services. The self-
description of pharmacy practice in the ICU is variable and 
poorly defined, with clinicians often describing their practice 
as being dependent on specific patient requirements. Clinical 
coverage models, patient load, and pharmacist training levels 
also differ. Documentation of drug therapy decisions largely 
relies on physicians’ progress notes, and the majority of 
pharmacist documentation occurs outside the legal record. 
However, clinical pharmacists are commonly expected to 
document their interventions, and doing so has been shown to 
have benefits in terms of cost avoidance. Work, research, and 
programming to decrease barriers to pharmacist 
documentation are ongoing. However, the critical care 
pharmacist should be responsible for comprehensive 
medication management that includes: 
 Participation in interprofessional rounding, patient care 
meetings, and code arrests. 
 Performance of patient admission medication histories, 
medication reconciliation, and patient profile reviews. 
This proposal will allow us to move from 45% to 100% 
coverage of this key metric in surgical ICU patients. 
 Involvement in transfer/discharge medication 
consultation. The critical care pharmacist will focus on 
moving to oral meds from IV and on reducing medications 
that result in longer term ICU stays, such as sedatives and 
pain medications, to minimize ICU length of stay. 
 Involvement in medication use review (as appropriate). 
 Service as a mentor/educator to trainees (pharmacy, 
nursing, and medicine). 
 Support of quality improvement and research initiatives. 
 Service as an educator and medication information 
resource that is easily accessible to ICU clinicians. 
 Performance of medication order review for cost 
effectiveness and appropriateness. 
 Implementation and demonstration of cost-savings 
initiatives related to medications. 
 Service as a leader for critical care pharmacy services [28-
30]. 
 
3. ICU Medication management 
In addition to processing medication orders and coordinating 
the arrival of medications, pharmacists can also assist with 
therapeutic drug monitoring (vancomycin, aminoglycosides, 
and warfarin), medication dosing, renal dosing, and 
responding to medical emergencies (stroke, code blue, 
therapeutic hypothermia, rapid sequence intubation, etc). 
 
3.1. Medication labeling 
Medication vials, liquid medication cups, intravenous (IV) 
medication bags, and packaging that have similar labeling font, 
font size, and color scheme trigger misperception and mix-ups 
at every stage of the medication use process. These look-alike 
medications contribute to medication errors and are of utmost 
concern at the time of dispensing and administration. 
Containers within or across a product line should not be similar 
in appearance. Different strengths and product or vial sizes 
should be distinguishable by size, color, shape, or some other 
mechanism [31]. 
 
3.2. Route-specific problems related to drug formulation 
design 
Absorption is another commonly cited issue with enteral 
administration of a medication in critical care. Medications 
administered via a naso-jejunal or jejunostomy tube bypass 
the duodenum, the principle absorption site for most 
medications, leading to variable effects on absorption and 
first-pass metabolism. The absorption of some medications 
can be affected by concomitant administration with enteral 
nutrition (eg, warfarin, phenytoin, levothyroxine), and so 
special care must be taken to appropriately interrupt enteral 
nutrition around the timing of drug administration.  Even if a 
medication is able to be administered to the stomach or 
duodenum, small bowel resection, gastroparesis, ileus, and 
decreased splanchnic flow all have the potential to affect 
absorption and efficacy. However, clinicians may also 
overestimate the absorptive problem and decline to use an 
enteral formulation in a patient who could actually benefit 
from it. Additional research into how these problems affect 
medication absorption in critically ill patients would help 
guide decision-making in this population [32-34]. 
A. Enteral route of administration: Access issues related to 
enterally administered medications are encountered 
frequently in critical care. Medications that are only 
available in an enteral formulation pose a problem for 
patients with a strict nothing by mouth (NPO) order. 
Carbidopa/levodopa, which is only available as an enteral 
formulation, is one example. Related to this challenge is 
the problem of medication administration via small-bore 
feeding tubes. Because of the small lumen, these tubes 
are prone to becoming clogged and, as many are placed 
in the duodenum or jejunum, they are also difficult to 
replace. For these reasons, clinicians often decide against 
administering crushed medications via small bore 
feeding tubes. Some medications are available as 
manufactured suspensions for enteral administration, 
but most are not. Pharmacies can prepare suspensions of 
some medications when they are not commercially 
available, but not all drugs can be adapted to a 
suspension, and stability information is often limited. 
Another issue related to enteral access is immediate-
release (IR) versus extended-release (ER) formulations of 
medications. These different formulations are often 
confusing for clinicians, and the differences between the 
formulations vary from drug to drug. For a patient who 
receives medications via a nasogastric tube, it would be 
appropriate to crush a metoprolol tartrate tablet (the IR 
formulation), but crushing a metoprolol succinate tablet 
(the ER formulation) could lead to a more rapidly 
profound, yet un-sustained, effect than is desired. The 
problem of tablet crushing is not unique to drugs with an 
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IR and ER formulation. A number of medications should 
not be crushed for a variety of reasons, ranging from 
onset of effect to cytotoxic potential [35,36]. 
B. Subcutaneous (SC) route of administration: Accuracy of 
administration, specifically the depth of injection, is a 
concern with medications administered subcutaneously. 
Variable absorption is also a concern with 
subcutaneously-administered medications in critically ill 
patients. It has been suggested that hemodynamic 
instability, vasoactive medications, and fluid shifts may 
alter the absorption of medications such as 
subcutaneous insulin and heparin, but the data are 
conflicting. Additionally, the prescribing information 
would include details about pharmacokinetics and 
pharmacodynamics specifically in critically ill patients 
[37,38]. 
C. Intramuscular (IM) route of administration: 
Intramuscular medications are subject to the same 
problem of administration accuracy as subcutaneous 
medications. Inadvertent administration of these 
medications to tissue other than muscle could lead to 
differences in absorption and effect. Additionally, many 
critically ill patients experience muscle wasting, which 
further complicates this route of administration. 
Intramuscular administration of medications poses a risk 
of hematoma in any patient. In the critically ill 
population, where many patients are anticoagulated or 
coagulopathic, the concern for hematoma is even 
greater. Although data suggest intramuscular injection 
may be safe in anticoagulated patients, it is generally 
avoided whenever possible.  “IM better than SC” involves 
epinephrine. “SC better than IM” involves interferon-
beta-1a, methotrexate, human chorionic gonadotropin, 
hepatitis B immunoglobulin, hydrocortisone, and 
morphine. [39,40]. 
D. Intravenous (IV) route of administration: Intravenous 
fluid therapy is one of the most common interventions in 
acutely ill patients. Each day, over 20% of patients in 
intensive care units (ICUs) receive intravenous fluid 
resuscitation, and more than 30% receive fluid 
resuscitation during their first day in the ICU. Virtually all 
hospitalized patients receive intravenous fluid to 
maintain hydration and as diluents for drug 
administration. Because medications delivered via the IV 
route pharmacokinetically bypass an absorption phase, 
they cause systemic effects within seconds of 
administration, making this route especially important 
for critically ill patients. These same characteristics also 
leave patients vulnerable to harm from IV-associated 
medication errors. Incorrect dosing and rates, including 
unintentional bolus administration, are common errors 
encountered with IV medication administration. IV 
medications that require further dilution before safe 
administration should never be packaged in a manner 
that suggests or could allow for direct administration (eg, 
prefilled syringes). Additionally, medications that require 
mixing before use or administration should be avoided, 
and when absolutely necessary, should be labeled as 
such. A number of medications in the ICU are provided 
via continuous infusion. As a result, large fluid volumes 
might be administered to patients who are already 
volume overloaded or have one or more electrolyte 
abnormality. The requirement for a carrier fluid may 
complicate this challenge even further in critically ill 
patients. The use of a high carrier rate allows the drug to 
reach the patient quickly and minimizes the time to a 
systemic effect after a change in rate, especially with 
vasoactive medications. However, use of a high carrier 
rate increases the risk of infusing an unintentional 
medication bolus when changes are made to either the 
carrier rate or drug infusion rate. Ideally the medications 
delivered to ICU patients should be easily titratable, 
meaning they have a rapid onset; have a short half-life; 
are supplied in standard-concentration, inexpensive, 
ready-to-use bags; and are not extremely concentrated 
(requiring a carrier fluid) or diluted (minimizing the 
volume required to deliver the drug). Smart infusion 
pumps with integrated decision support represent a 
targeted approach to minimize IV-associated medication 
errors. However, the presence of smart infusion pumps 
alone does not decrease serious medication errors. 
Smart infusion pumps were designed to promote safety 
and simplify medication administration. These pumps 
can store large drug libraries with information about 
weight-based dosing, standard infusion rates, and 
maximum infusion rates. They can also enforce these 
parameters to prevent inappropriate infusion rates and 
errors. Kopp et al. reported lack of drug knowledge was 
the cause of 10% of errors and slips and memory lapses 
were responsible for 40% of errors at the administration 
stage. Some pumps can be accessed wirelessly, allowing 
an entire fleet of pumps to be updated simultaneously. 
“SC better than IV” involves trastuzumab, rituximab, 
antitumor necrosis factor medications, bortezomib, 
amifostine, recombinant human granulocyte-
macrophage colony-stimulating factor, granulocyte 
colony-stimulating factor, recombinant interleukin-2, 
immunoglobulin, epoetin alfa, heparin, and opioids. “IV 
better than SC” involves ketamine, vitamin K1, and 
abatacept. With respect to insulin and ketamine, 
whether IV has advantages over SC is determined by 
specific clinical circumstances. “IM better than IV” 
involves epinephrine, hepatitis B immunoglobulin, peg-
aspargase, and some antibiotics. “IV better than IM” 
involves ketamine, morphine, and antivenom [31], [40-
44]. 
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Exhibit 3. Specific Error Problem Areas of IV Administration 
 Pumps programmed incorrectly 
 Drug injected too fast 
 Drug injected through wrong type of access, oral medication injected 
 Similar labeling 
 Stressful situation 
 Wrong drug taken from drug dispensing machine 
 Wrong amount of fluid aspirated from drug vial containing more drug than ordered 
 Obtained drug from drug dispensing machine in advance, then order was changed but nurse not 
aware 
 Mixed up hanging IV bags changing dose rate on wrong drug 
 
In the US, 60% of serious and life-threatening medication 
errors that occur in patients involved IV drugs; in the UK 
approximately 56% of the errors administered with IV drugs. 
Although only a few medications are administered IV in the 
hospital setting, the IV drugs account for the majority of 
medication errors. A high incidence of medication errors 
related to IV therapy was found in Germany, where 23% of the 
total medication errors occur during IV administration. 
However, there are also a lot of possible direct and negative 
side effects such as pulmonary complications, 
thrombophlebitis, and infection with the possibility of sepsis. 
There have been reports of death and harm following 
medication errors such as wrong dose drug diluents and cross 
contamination errors. Thus, the primary focus should be to 
identify IV therapy associated drug-related problems (DRPs). 
Nurses often cited lack of experience with the patient 
population, drug dosage, administration route (i.e. 
intrathecal), or a stressful and busy environment for the 
occurrence of error. Safety, efficacy, patient preference, and 
pharmacoeconomics are four principles governing the choice 
of injection route. Safety and efficacy must be the preferred 
principles to be considered (eg, epinephrine should be given 
intramuscularly during an episode of systemic anaphylaxis). If 
the safety and efficacy of two injection routes are equivalent, 
clinicians should consider more about patient preference and 
pharmacoeconomics because patient preference will ensure 
optimal treatment adherence and ultimately improve patient 
experience or satisfaction, while pharmacoeconomic concern 
will help alleviate nurse shortages and reduce overall health 
care costs. Besides the principles, the following detailed 
factors might affect the decision: patient characteristics-
related factors (body mass index, age, sex, medical status [eg, 
renal impairment, comorbidities], personal attitudes toward 
safety and convenience, past experience, perception of 
current disease status, health literacy, and socioeconomic 
status), medication administration-related factors (anatomical 
site of injection, dose, frequency, formulation characteristics, 
administration time, indication, flexibility in the route of 
administration), and health care staff/institution-related 
factors (knowledge, human resources) [40,41], [45]. 
 
E. Transdermal route of administration: A number of 
safety concerns surround use of the transdermal route in 
critically ill patients. Transdermal drug delivery is erratic 
in critically ill patients. Because perfusion to epidermal 
and subcutaneous tissue is often lower than normal, it 
can cause unpredictable and often less-than-optimal 
absorption. On the other hand, elevated core 
temperature and febrile states, which are not 
uncommon in critically ill patients, increase absorption 
and the risk of excessive drug release. Many patches 
include aluminum backing, making them unsafe for wear 
in a magnetic resonance imaging machine. It is for these 
reasons that medication delivery via the transdermal 
route should largely be avoided in critically ill patients. If 
patients are admitted to the ICU wearing a transdermal 
medication patch, it should be discontinued as soon as 
possible, and other more reliable routes should be 
utilized. The transdermal route should not be a target for 
novel drug delivery in the critically ill patient population 
[46] 
F. Epidural route of administration: Epidural analgesia (EA) 
is one of the most widely utilized neural deafferentation 
techniques. It is used for analgesia during the 
perioperative period, but also for obstetrics labor and 
trauma as well as in the treatment of acute, chronic and 
cancer-related pain. Its objective is not only to block 
noxious afferent stimuli, but also to induce bilateral 
selective thoracic sympathetic blockade. In addition to 
analgesia itself, the modulatory effects of thoracic EA 
could improve organ perfusion with reduced 
complications in the perioperative period, thus possibly 
decreasing postoperative complications, shortening 
hospital stay and improving survival. Local anesthetics 
(eg, bupivacaine, ropivacaine) must be used with caution 
in the ICU. Anesthesiologists must first verify that 
epidural catheters are indeed in the epidural space. Even 
when infused appropriately, local anesthetics 
administered via the epidural route can cause systemic 
vasodilation and hypotension. In critically ill patients, the 
risks and benefits should be weighed carefully. It may be 
most appropriate to use separate infusions for local 
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anesthetics and systemic opioids because the clinician 
can titrate each individually to minimize adverse effects. 
However, inadvertent systemic administration of local 
anesthetics can cause significant cardiotoxicity that could 
lead to arrhythmias, disturbances in contractility, or even 
cardiac arrest. A number of safety measures must be in 
place to prevent such mistakes. If not available 
commercially, infusions should be compounded in the 
pharmacy and not in the operating room or ICU. 
Medication bags and syringes should be labeled clearly 
with information regarding the route of administration if 
other than IV (eg, wording such as “epidural use only”). 
Independent double-checks should be implemented at 
the bedside when epidural medications are initiated and 
when rates or doses are changed [47-49]. 
 
3.3.  Parenteral nutrition support 
Nearly 40% of adult critically ill patients have a high risk of 
malnutrition, which definitely increases the incidence of 
mortality and poor prognosis. As a therapy, nutrition 
supplements have become important and necessary. In 
general, the individual benefits and risks of parenteral 
nutrition (PN) and enteral nutrition (EN) have been 
elucidated gradually. Because of cheaper, safer, and more 
physiologic, EN remains the preferred choice. But EN 
alone usually is not able to meet the energy targets owing 
to gastrointestinal intolerance. Parenteral nutrition (PN) 
therapy is a complex and critical therapy that requires 
special clinical knowledge, skills, and practice experience 
to avoid errors in prescribing, compounding, and clinical 
management of patients. It involves the IV administration 
of nutritionally sufficient and balanced formulations to 
supply essential nutrients to patients who are unable to 
tolerate oral or enteral feeding due to dysfunctional or 
inaccessible gastrointestinal (GI) tract. Over the years, PN 
has become an important primary and adjunctive therapy 
in various clinical conditions and disease states for both 
the acutely ill hospitalized patients and in the long-term 
setting for selected patients in the home. The PN 
formulations are complex admixtures that consist of 
multiple components, including both macronutrients 
(amino acids, dextrose, and IVFEs) and micronutrients 
(electrolytes, vitamins, and trace elements). When all the 
daily nutritional requirements are exclusively supplied to 
the patient by PN formulations, the therapy is called total 
parenteral nutrition (TPN). The PN formulations must 
meet the nutritional requirements of the patient 
according to patient age, energy expenditure, and clinical 
status to ensure that the appropriate nutrients are 
provided to patient and to avoid under- or overnutrition. 
Although being lifesaving for many patients, PN therapy is 
a high-risk feeding modality that can be associated with 
some complications. An incompatible, unstable, or 
contaminated intravenous infusion may result in harm to 
patients, including serious morbidity and even mortality. 
Therefore, PN formulations must be compounded under 
strict aseptic techniques according to validated 
pharmaceutical compounding procedures. Broyles et al 
reported the positive impact of pharmacists’ interventions 
on improving fluid balance in fluid-restricted ICU patients 
receiving PN.  The practice of permissive underfeeding in 
the medical or mixed medical-surgical ICU is supported by 
multiple small studies that suggest improved clinical 
outcomes compared with full feeding, potentially due to 
fewer complications from hyperglycemia, electrolyte 
imbalances, and feeding intolerances. Arabi et al found 
that permissive underfeeding was associated with lower 
(but non–statistically significant) 28-day mortality 
compared to target feeding [50-52]. 
 
4. Pharmacist on the Pediatric Intensive Care Practice 
Pharmacists are considered an integral part of the 
multidisciplinary team in ICU patient care, although their 
level of involvement in the critical care practice is variable. 
Studies have shown that a pharmacist's involvement in 
critical care rounds is associated with fewer adverse 
effects and alone may be associated with lower mortality 
among ICU patients. The American Academy of Pediatrics 
in 2003 proposed that inclusion of a pharmacist in the 
critical care team can help decrease medication errors. 
With transitions occurring in the field of clinical pharmacy, 
it is important to define the role of the clinical pharmacist 
on the multidisciplinary team and to highlight the value of 
the position, which includes enhancing the safety and 
quality of patient care, in addition to financial savings. 
Clinical pharmacists have been a part of the PICU team at 
our institution since 2003, with evolution of their role and 
involvement over time. The pharmacists working in the 
PICU have either completed a pediatric pharmacy 
residency or departmental pediatric pharmacy training. 
The use of antibiotics in PICU is very high (ranging from 
65% to more than 95%) due to several reasons including 
high incidence of community-acquired sepsis, healthcare-
associated infections or as a postoperative prophylaxis. 
This high antibiotic use leads to several problems 
including development of antibiotic resistance, drug 
toxicity and drug interactions. Pharmacist-led ASP in PICU 
ensured 64% reduction in antibiotics use and 58% cost 
reduction both in terms of DOT and COT. Having a 
pharmacist on a rounding team in an ICU has been shown 
to reduce the incidence of ADEs by two thirds. Pharmacist-
monitored TPN proved cost effective in comparison with 
the standardized solution without pharmacist monitoring. 
Thus, clinical pharmacists can not only improve drug 
safety, but also serve to lower costs, improve quality of 
pharmacotherapy, coordinate the relationship with other 
departments [53-55]. 
 
5. Interventions to reduce medication errors in NICU 
Medication errors represent a significant but often 
preventable cause of morbidity and mortality in neonates. 
Neonates are more prone to medication errors at each 
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stage of the medicine management process due to the 
increased need for calculations, dilutions, and 
manipulations of medications. Furthermore, many 
medications are used off-label in the neonatal setting, 
meaning that they are not specifically licensed for use in 
neonates and are therefore often only available in adult 
formulations and concentrations. As a result, prescribing 
and administration challenges often places neonates at 
risk of potentially fatal 10-fold or 100-fold dosing errors. 
There is also the associated challenge of limited dosing 
protocols and evidence-based information regarding the 
efficacy, safety, dosing, pharmacokinetic, and clinical use 
of medications in neonates. In addition, relative 
physiological immaturity means that neonates have less 
capacity in being able to buffer unintended consequences 
of medication errors. Such susceptibility towards 
medication errors in neonates, as previously described, is 
further emphasized by previous research that observed 
that medication errors with the potential to cause 
significant harm were three times more likely to occur in 
the NICU than in adult wards. Furthermore, an analysis of 
all medical errors occurring within the NICU identified that 
medication errors were the single largest contributor, 
nearly 50% of all errors. Given the complexity of 
medication use in neonates, the high frequency in which 
high-risk medications are used and the potential for 
serious adverse events of even minor medication errors, 
intervention strategies to increase medication safety in 
neonatal care should be regularly reviewed. The 
identification and evaluation of such interventions are of 
critical importance in assisting healthcare systems and 
providers in understanding, implementing, and 
augmenting interventions to reduce neonatal medication 
errors. Several international organizations have 
encouraged the conduct of pharmaceutical clinical trials 
with newborns in an attempt to overcome a number of 
barriers that have been identified, such as ethical issues 
involving this vulnerable population, low accrual rates 
because of the small size of this population, small volume 
of biological samples that can be obtained from neonates, 
changing pharmacokinetics and pharmacodynamics with 
the postnatal age, as well as financial considerations. The 
incidence of off-label and unlicensed medicines 
prescribed in NICU varies from 34% to 95.6% and from 
5.7% to 34.6%, respectively. Furthermore, 44% to 100% of 
all neonates hospitalized at NICUs are administered at 
least one off-label or one unlicensed medicine. The lack of 
information about the safety and efficacy of drugs 
increases the risk of poor clinical outcomes, of ADRs and 
medication errors when off-label and unlicensed 
medicines are prescribed to neonates. The conversion of 
solid to liquid pharmaceutical forms represents about 
one-sixth of the unlicensed drugs administered in NICUs, 
and this practice occurs mostly with cardiovascular 
medicines because of the unavailability in the market of 
liquid formulations adequate for administration to the 
neonatal population, a reality observed in several 
countries. Drug shortages affected many agents used in 
NICUs, which can have quality and safety implications for 
patient care, especially in extremely low birth weight 
infants. Neonatologists must be aware of current 
shortages and implement mitigation strategies to 
optimize patient care. In the context of the continuous 
quest to improve the care of the neonates especially the 
critically ill premature infants, the extended role of 
pharmacists in the process of parenteral nutrition order 
writing and effective participation in decision-making 
especially in the neonatal population is increasingly 
important [56-61]. 
 
6. Pharmacists in CCU  
The in-hospital mortality rate of acute myocardial 
infarction (AMI) has dramatically decreased due to the 
treatment at the coronary care unit (CCU), especially with 
the progress of arrhythmia therapy and reperfusion 
therapy. On the other hand, severe heart failure and 
multiple organ failure are increasing due to aging 
populations and multiple organ diseases. As a result, 
patients with AMI without complications are less likely to 
be admitted to the CCU, and cardiologists staying in the 
CCU have also decreased. The mortality rate is high when 
complications such as cardiogenic shock, cardiac rupture, 
and in-hospital cardiac arrest occur in AMI, therefore 
careful intensive care even in low-risk AMI is necessary. 
Therefore, for the critical care of cardiovascular diseases, 
it is necessary to convert from CCU to the cardiovascular 
intensive care unit. DRPs that were suspected to cause or 
contribute to a possibly fatal outcome were determined 
by clinical pharmacist service in patients hospitalized in a 
cardiology ward. Correction of these DRPs by physicians 
after pharmacist’s advice caused a significant decrease in 
mortality as analyzed by PS matching. In patients with 
CVDs, the frequency of DRPs has been reported to be as 
high as 68%. Cardiovascular drugs, such as antithrombotic 
agents, anticoagulants, hemostatic agents, and cardiac 
glycoside, are commonly implicated in FADE due to 
suboptimal medication use in CVD. Nosocomial infections 
in patients in cardiology departments rely on factors such 
as old age, HF, invasive procedures, concomitant diseases, 
and inappropriate use of antimicrobial drugs. These 
infections ultimately increase the risk of death for these 
patients. The clinical pharmacists can play an important 
role by intervening and correcting DRPs at a hospital 
cardiology unit. It is likely that the clinical pharmacy 
intervention is best implemented in the cardiology ward if 
the clinical pharmacist discusses the DRPs face-to-face 
with the physicians. A pharmacist's clinical services in the 
CCU allowed for significant estimated reductions in total 
drug costs [62-64].  
 
7. Education and Training ICU Pharmacists 
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As healthcare system has begun to place more emphasis 
on the provision of direct patient care activities and 
adherence to clinical guidelines, the profession of 
pharmacy has adapted to provide services, and 
practitioners, that meet these demands. A rising 
proportion of end-of-life care takes place in the ICU. 
Nearly 30% of Medicare patients used the ICU in their last 
month of life, increased from 24% a decade ago. Training 
for ICU pharmacotherapy is usually not the focus of many 
undergraduate pharmacy curricula and ICU clinical 
rotations/clerkships are often viewed by students as 
‘difficult to pass’ rotations. Therefore, students’ interest 
in ICU as a practice area is not widespread, limiting the 
qualified recruitment pool when a position is secured. 
Fortunately, with dedicated courses in ICU 
pharmacotherapy appearing in the elective portion of 
some pharmacy curricula, the addition of board 
certification in Critical Care Pharmacy by the Board of 
Pharmacy Specialties in the U.S., more and more training 
programs and opportunities will be forthcoming to help 
close the qualified personnel shortage and needs gap. In 
Japan, initiation of the reimbursement from the 
government to monitor patients in ICU and the foundation 
of certified emergency medicine and critical care specialist 
resulted in the increased number of ICU pharmacists. 
Pharmacists keen on a career in critical care need to 
understand that this is a complicated area and that things 
do not always end well for patient. Ongoing professional 
development and collegial support is even encouraged 
internationally. This may include undertaking more 
research or developing better ways of working within a 
team and developing treatment plans, prescribing 
medications and leading a pain, agitation and delirium 
service, ensuring patients received the correct sedatives, 
opioid analgesics and antipsychotics. The interventions 
listed above are only a few of many responsibilities of a 
critical care pharmacist. These pharmacists may also work 
up patients, and round with the multidisciplinary team. In 
addition, critical care pharmacists communicate current 
drug shortages and substitutions to the team on their unit. 
Overall, working in the intensive care unit appears to 
provide critical care pharmacists the opportunity to use 
their clinical knowledge to enhance patient care as a 
valued member of the interprofessional team. Quality of 
palliative care training in critical care medicine programs 
and the use of bedside tools were independently 
associated with reduced ICU use at the end of life. Hospital 
and medical education leaders have worked to address 
concerns about the increasing amount and significant 
variation in end-of-life ICU use. Individual institutions 
have developed and evaluated a variety of interventions 
that include a more proactive approach to the provision of 
palliative care, educational initiatives targeting ICU staff, 
and bedside tools for communication and symptom 
management. Innovations in workforce training and 
technology specific to the ICU may be useful in addressing 
the shortage of intensivist physicians, yielding benefits to 
patients and payers [65-71]. 
 
8. Epilogue 
Even as the scope of pharmacy practice expands, impediments 
to optimal delivery of pharmaceutical care remain. These 
include shortages of pharmacists, increasing complexity of 
medication regimens, and increasing acuity of patients and the 
associated workload. Pharmacy technicians are well 
positioned to augment direct patient care services because of 
their knowledge of the medication distribution system in their 
respective health care centers. Pharmacy technicians with 
additional training and support in the clinical area increase the 
work efficiency of pharmacists in the ICU, thereby making it 
possible to extend pharmacy services in direct patient care to 
a larger number of patients during the pharmacists’ work day. 
Recent literature indicates that more active participation of 
pharmacists in the pharmacological treatment of critically ill 
patients is desirable. Moreover, according to the literature, 
pharmacist’s actions in the ICU should not be limited to 
providing advice to the staff but should also include active 
participation in decision-making regarding the maintenance of 
pharmacological treatment. 
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